Jump to content

Main Page: Difference between revisions

From Neoplasm
← Older edit
VisualWikitext
No edit summary
%login% (talk | contribs)
37 edits
m Replaced content with "%About_Yourself%"
Tags: Replaced Manual revert
 
(126 intermediate revisions by 62 users not shown)
Line 1: Line 1:
{{DISPLAYTITLE:<span style="display: none"></span>}}
%About_Yourself%
__NOTOC__
<!--Hides title of Main Page-->
<div style="text-align:center">
<h1>'''HemOnc.org - A Human-Curated Hematology/Oncology Reference'''</h1>
</div>
 
<div style="text-align:center"><big>HemOnc.org is the largest freely available medical wiki of [[:Category:Intervention_index|interventions]], [[:Category:Regimen_index|regimens]], and [[:Category:General_reference_pages|general information]] relevant to the fields of hematology and oncology. Any healthcare professional can [[How to contribute|sign up to contribute]]; the [[Eligibility criteria|accuracy and completeness of content]] is overseen by the [[Editorial Board]]. If this is your first time visiting, please start with the '''[[Tutorial|the tutorial page]]''', review our '''[[philosophy]]''', or just start exploring!</big></div>
 
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;"
|-
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|[[Tutorial#Regimens|<span style="color:black;">Regimens</span>]]: 5,549
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">[[Guidelines]]: 1,173</span>
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">Studies</span>: 7,123
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">References</span>: 10,098
|-
|}
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;"
|-
|style="width: 20%; font-size:125%; background-color:#08519c"|[[#solidtumors|<span style="color:white;">Solid Tumors</span>]]
|style="width: 20%; font-size:125%; background-color:#cf0001"|[[#malignantheme|<span style="color:white;">Malignant Hematology</span>]]
|style="width: 20%; font-size:125%; background-color:#ba871a"|[[#peds|<span style="color:white;">Pediatrics</span>]]
|style="width: 20%; font-size:125%; background-color:#4a1486"|[[#transplant|<span style="color:white;">Transplant & IEC</span>]]
|style="width: 20%; font-size:125%; background-color:#31a354"|[[#classicalheme|<span style="color:white;">Classical Hematology</span>]]
|-
|}
 
==Links to all main disease pages==
<span id="solidtumors"></span>
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#08519c"| '''Solid Tumors'''
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Breast Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Early breast cancer (EBC)'''
|-
|style="background-color:#eff3ff"|[[Early breast cancer|EBC, NOS]]
|style="background-color:#eff3ff"|[[Early breast cancer, HR-positive|HR-positive EBC]]
|style="background-color:#eff3ff"|[[Early breast cancer, HER2-positive|HER2-positive EBC]]
|style="background-color:#eff3ff"|[[Early breast cancer, HER2-low|HER2-low EBC]]
|-
|style="background-color:#eff3ff"|[[Early breast cancer, HR and HER2 co-expressing|HR-positive and HER2-positive EBC]]
|style="background-color:#eff3ff"|[[Early breast cancer, triple negative|Early triple-negative breast cancer (eTNBC)]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Metastatic breast cancer (MBC)'''
|-
|style="background-color:#eff3ff"|[[Metastatic breast cancer|MBC, NOS]]
|style="background-color:#eff3ff"|[[Metastatic breast cancer, HR-positive|HR-positive MBC]]
|style="background-color:#eff3ff"|[[Metastatic breast cancer, HER2-positive|HER2-positive MBC]]
|style="background-color:#eff3ff"|[[Metastatic breast cancer, HER2-low|HER2-low MBC]]
|-
|style="background-color:#eff3ff"|[[Metastatic breast cancer, HR and HER2 co-expressing|HR-positive and HER2-positive MBC]]
|style="background-color:#eff3ff"|[[Metastatic breast cancer, triple negative|Metastatic triple-negative breast cancer (mTNBC)]]
|style="background-color:#eff3ff"|[[Breast cancer, CNS metastases|CNS metastases]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Breast cancer with molecular alterations'''
|-
|style="background-color:#eff3ff"|[[Test|Test]]
|style="background-color:#eff3ff"|[[Metastatic breast cancer, PI3K pathway-altered|PI3K pathway-altered Breast cancer]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Dermatologic Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Melanoma'''
|-
|style="background-color:#eff3ff"|[[Melanoma|Melanoma, NOS]]
|style="background-color:#eff3ff"|[[Melanoma,_BRAF-mutated|BRAF-mutated Melanoma]]
|style="background-color:#eff3ff"|[[Melanoma,_KIT-mutated|KIT-mutated Melanoma]]
|style="background-color:#eff3ff"|[[Melanoma,_NRAS-mutated|NRAS-mutated Melanoma]]
|-
|style="background-color:#eff3ff"|[[Uveal melanoma]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Non-melanoma skin cancer (NMSC)'''
|-
|style="background-color:#eff3ff"|[[Cutaneous basal cell carcinoma | Cutaneous BCC]]
|style="background-color:#eff3ff"|[[Cutaneous squamous cell carcinoma | Cutaneous SCC]]
|style="background-color:#eff3ff"|[[Merkel cell carcinoma|Merkel cell carcinoma (MCC)]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Endocrine Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Other endocrine cancers'''
|-
|style="background-color:#eff3ff"|[[Adrenocortical carcinoma]]
|style="background-color:#eff3ff"|[[Neuroendocrine tumor|Neuroendocrine tumor (NET)]]
|style="background-color:#eff3ff"|[[Neuroendocrine carcinoma|Neuroendocrine carcinoma (NEC)]]
|style="background-color:#eff3ff"|[[Pancreatic NET]]
|-
|style="background-color:#eff3ff"|[[Pheochromocytoma]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Thyroid cancer without molecular alterations'''
|-
|style="background-color:#eff3ff"|[[Thyroid cancer|Thyroid cancer, NOS]]
|style="background-color:#eff3ff"|[[Thyroid cancer, anaplastic|Anaplastic thyroid cancer (ATC)]]
|style="background-color:#eff3ff"|[[Thyroid cancer, differentiated|Differentiated thyroid cancer (DTC)]]
|style="background-color:#eff3ff"|[[Thyroid cancer, medullary|Medullary thyroid cancer (MTC)]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Thyroid cancer with molecular alterations'''
|-
|style="background-color:#eff3ff"|[[Thyroid_cancer,_BRAF-mutated|BRAF-mutated Thyroid cancer]]
|style="background-color:#eff3ff"|[[Thyroid_cancer,_RET-positive|RET-positive Thyroid cancer]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Gastrointestinal Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Upper GI tract'''
|-
|style="width: 25%; background-color:#eff3ff"|[[Esophageal cancer|Esophageal cancer, NOS]]
|style="width: 25%; background-color:#eff3ff"|[[Esophageal adenocarcinoma]]
|style="width: 25%; background-color:#eff3ff"|[[Esophageal squamous cell carcinoma|Esophageal squamous cell carcinoma (ESCC)]]
|style="width: 25%; background-color:#eff3ff"|[[Gastric cancer|Gastric cancer, NOS]]
|-
|style="width: 25%; background-color:#eff3ff"|[[Gastric cancer, HER2-positive|HER2-positive gastric cancer]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Lower GI tract'''
|-
|style="width: 25%; background-color:#eff3ff"|[[Anal cancer]]
|style="width: 25%; background-color:#eff3ff"|[[Appendiceal tumor]]
|style="width: 25%; background-color:#eff3ff"|[[Colon cancer|Colon cancer, NOS]]
|style="width: 25%; background-color:#eff3ff"|[[Colon cancer, RAS wild-type|RAS wild-type colon cancer]]
|-
|style="width: 25%; background-color:#eff3ff"|[[Colorectal cancer|Colorectal cancer (CRC), NOS]]
|style="width: 25%; background-color:#eff3ff"|[[Colorectal cancer, BRAF-mutated|BRAF-mutated CRC]]
|style="width: 25%; background-color:#eff3ff"|[[Colorectal cancer, HER2-positive|HER2-positive CRC]]
|style="width: 25%; background-color:#eff3ff"|[[Colorectal cancer, MSI-H or dMMR|MSI-H or dMMR CRC]]
|-
|style="width: 25%; background-color:#eff3ff"|[[Colorectal cancer, RAS wild-type|RAS wild-type CRC]]
|style="width: 25%; background-color:#eff3ff"|[[Rectal cancer]]
|style="width: 25%; background-color:#eff3ff"|[[Small bowel adenocarcinoma]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Hepatobiliary cancer'''
|-
|style="width: 25%; background-color:#eff3ff"|[[Biliary tract cancer]]
|style="width: 25%; background-color:#eff3ff"|[[Cholangiocarcinoma]]
|style="width: 25%; background-color:#eff3ff"|[[Gallbladder cancer]]
|style="width: 25%; background-color:#eff3ff"|[[Hepatocellular carcinoma|Hepatocellular carcinoma (HCC)]]
|-
|style="width: 25%; background-color:#eff3ff"|[[Periampullary adenocarcinoma]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Pancreatic cancer'''
|-
|style="width: 25%; background-color:#eff3ff"|[[Pancreatic cancer|Pancreatic adenocarcinoma, NOS]]
|style="width: 25%; background-color:#eff3ff"|[[Pancreatic cancer, BRCA-mutated|BRCA-mutated Pancreatic adenocarcinoma]]
|style="width: 25%; background-color:#eff3ff"|[[Pancreatic cancer, NRG1-positive|NRG1-positive Pancreatic adenocarcinoma]]
|style="width: 25%; background-color:#eff3ff"|[[Pancreatic NET]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Genitourinary Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Kidney cancer'''
|-
|style="background-color:#eff3ff"|[[Renal cell carcinoma|Renal cell carcinoma (RCC), NOS]]
|style="background-color:#eff3ff"|[[Clear cell renal cell carcinoma|Clear cell RCC (ccRCC)]]
|style="background-color:#eff3ff"|[[Non-clear cell renal cell carcinoma|Non-clear cell RCC (nccRCC)]]
|style="background-color:#eff3ff"|[[Papillary renal cell carcinoma|Papillary RCC]]
|-
|style="background-color:#eff3ff"|[[Sarcomatoid renal cell carcinoma|Sarcomatoid RCC]]
|style="background-color:#eff3ff"|[[Renal_cell_carcinoma,_VHL-associated|VHL-associated RCC]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Male genital tract'''
|-
|style="background-color:#eff3ff"|[[Penile cancer]]
|style="background-color:#eff3ff"|[[Prostate cancer|Prostate cancer, NOS]]
|style="background-color:#eff3ff"|[[Prostate cancer, HRD-positive]]
|style="background-color:#eff3ff"|[[Testicular cancer]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Urinary tract cancer'''
|-
|style="background-color:#eff3ff"|[[Urothelial carcinoma|Urothelial carcinoma, NOS]]
|style="background-color:#eff3ff"|[[Bladder cancer]]
|style="background-color:#eff3ff"|[[Upper tract urothelial carcinoma|Upper tract urothelial carcinoma (UTUC)]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Gynecologic Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Ovarian cancer'''
|-
|style="background-color:#eff3ff"|[[Ovarian cancer|High-grade serous ovarian cancer (HGSOC)]]
|style="background-color:#eff3ff"|[[Low-grade serous ovarian cancer|Low-grade serous ovarian cancer (LGSOC)]]
|style="background-color:#eff3ff"|[[Ovarian cancer, BRCA-mutated]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Other gynecologic cancer'''
|-
|style="background-color:#eff3ff"|[[Cervical cancer]]
|style="background-color:#eff3ff"|[[Endometrial cancer]]
|style="background-color:#eff3ff"|[[Gestational trophoblastic neoplasia]]
|style="background-color:#eff3ff"|[[Vulvar cancer]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Head & Neck Oncology'''
|-
|style="background-color:#eff3ff"|[[Head and neck cancer]]
|style="background-color:#eff3ff"|[[Nasopharyngeal carcinoma|Nasopharyngeal carcinoma (NPC)]]
|style="background-color:#eff3ff"|[[Oropharyngeal_cancer,_HPV-positive|HPV+ Oropharyngeal cancer]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Mesothelioma'''
|-
|colspan="2" style="background-color:#eff3ff"|[[Malignant peritoneal mesothelioma|Malignant peritoneal mesothelioma (MPEM)]]
|colspan="2" style="background-color:#eff3ff"|[[Malignant pleural mesothelioma|Malignant pleural mesothelioma (MPM)]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Neuro-Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Primary central nervous system (CNS) malignancies'''
|-
|style="background-color:#eff3ff"|[[Anaplastic glioma]]
|style="background-color:#eff3ff"|[[Craniopharyngioma]]
|style="background-color:#eff3ff"|[[Diffuse midline glioma]] <span style="color: red"><small>New</small></span>
|style="background-color:#eff3ff"|[[Glioblastoma|Glioblastoma (GBM)]]
|-
|style="background-color:#eff3ff"|[[Low-grade glioma]]
|style="background-color:#eff3ff"|[[Meningioma]]
|style="background-color:#eff3ff"|[[Subependymal giant cell astrocytoma|Subependymal giant cell astrocytoma (SEGA)]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Secondary CNS malignancies'''
|-
|style="background-color:#eff3ff"|[[CNS carcinoma]]
|style="background-color:#eff3ff"|[[CNS leukemia]]
|style="background-color:#eff3ff"|[[CNS lymphoma]]
|style="background-color:#eff3ff"|[[CNS melanoma]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Sarcoma'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Bone sarcoma'''
|-
|style="background-color:#eff3ff"|[[Bone sarcoma|Bone sarcoma, NOS]]
|style="background-color:#eff3ff"|[[Ewing sarcoma]]
|style="background-color:#eff3ff"|[[Giant-cell tumor of bone]]
|style="background-color:#eff3ff"|[[Osteosarcoma]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Soft tissue sarcoma'''
|-
|style="background-color:#eff3ff"|[[Soft tissue sarcoma|Soft tissue sarcoma (STS), NOS]]
|style="background-color:#eff3ff"|[[Alveolar soft part sarcoma|Alveolar soft part sarcoma (ASPS)]]
|style="background-color:#eff3ff"|[[Dermatofibrosarcoma protuberans]]
|style="background-color:#eff3ff"|[[Desmoid tumor]]
|-
|style="background-color:#eff3ff"|[[Epithelioid sarcoma]]
|style="background-color:#eff3ff"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]]
|style="background-color:#eff3ff"|[[Inflammatory myofibroblastic tumor|Inflammatory myofibroblastic tumor (IMT)]]
|style="background-color:#eff3ff"|[[Leiomyosarcoma|Leiomyosarcoma (LMS)]]
|-
|style="background-color:#eff3ff"|[[Liposarcoma]]
|style="background-color:#eff3ff"|[[PEComa]]
|style="background-color:#eff3ff"|[[Rhabdomyosarcoma|Rhabdomyosarcoma (RMS)]]
|style="background-color:#eff3ff"|[[Tenosynovial giant cell tumor|Tenosynovial giant cell tumor (TGCT)]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Vascular sarcoma'''
|-
|style="background-color:#eff3ff"|[[Vascular sarcoma|Vascular sarcoma, NOS]]
|style="background-color:#eff3ff"|[[Angiosarcoma]]
|style="background-color:#eff3ff"|[[Kaposi sarcoma|Kaposi sarcoma (KS)]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Thoracic Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Non-small cell lung cancer (NSCLC) without driver alterations'''
|-
|style="background-color:#eff3ff"|[[Non-small cell lung cancer |NSCLC, NOS]]
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, nonsquamous|Nonsquamous NSCLC]]
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, squamous|Squamous NSCLC]]
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, PD-L1-positive|PD-L1-positive NSCLC]]
|-
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_CNS_metastases|CNS metastases]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''NSCLC with driver alterations'''
|-
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_ALK-positive|ALK-positive NSCLC]]
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_BRAF-mutated|BRAF-mutated NSCLC]]
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, c-Met-positive|c-Met-positive NSCLC]]
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_EGFR-mutated|EGFR-mutated NSCLC]]
|-
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_HER2-mutated|HER2-mutated NSCLC]]
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_KRAS-mutated|KRAS-mutated NSCLC]]
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, MET-mutated|MET-mutated NSCLC]]
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, NRG1-positive|NRG1-positive NSCLC]]
|-
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, RET-positive|RET-positive NSCLC]]
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_ROS1-positive|ROS1-positive NSCLC]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Other thoracic cancer'''
|-
|style="background-color:#eff3ff"|[[Malignant pleural mesothelioma|Malignant pleural mesothelioma (MPM)]]
|style="background-color:#eff3ff"|[[Small cell lung cancer |Small cell lung cancer (SCLC)]]
|style="background-color:#eff3ff"|[[Thymoma]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Site-agnostic'''
|-
|style="background-color:#eff3ff"|[[BRAF]]
|style="background-color:#eff3ff"|[[EGFR]]
|style="background-color:#eff3ff"|[[ERBB2 (HER2)]]
|style="background-color:#eff3ff"|[[ERBB3 (HER3)]]
|-
|style="background-color:#eff3ff"|[[MSI-H or dMMR]]
|style="background-color:#eff3ff"|[[NTRK]]
|style="background-color:#eff3ff"|[[RET]]
|style="background-color:#eff3ff"|[[SMO or PTCH-1 (Hedgehog)]]
|-
|style="background-color:#eff3ff"|[[TMB-H]]
|style="background-color:#eff3ff"|[[Carcinoma of unknown primary|Carcinoma of unknown primary (CUP)]]
|-
|}
<span id="malignantheme"></span>
 
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#cf0001"| '''Malignant Hematology'''
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Acute leukemias'''
|-
|style="width: 25%; background-color:#fee0d2"|[[Acute leukemia, KMT2A-rearranged]]
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia | Acute myeloid leukemia (AML)]]
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, FLT3-positive | AML, FLT3-positive]]
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, IDH-mutated | AML, IDH-mutated]]
|-
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, NPM1-mutated | AML, NPM1-mutated]]
|style="width: 25%; background-color:#fee0d2"|[[Acute promyelocytic leukemia | Acute promyelocytic leukemia (APL)]]
|style="background-color:#fee0d2"|[[B-cell acute lymphoblastic leukemia | B-cell acute lymphoblastic leukemia (B-ALL)]]
|style="background-color:#fee0d2"|[[B-cell acute lymphoblastic leukemia, Ph-positive | B-ALL, Ph+]]
|-
|style="background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia (T-ALL)]]
|style="background-color:#fee0d2"|[[Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm (BPDCN)]]
|style="background-color:#fee0d2"|[[CNS leukemia]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Myeloproliferative neoplasms and myelodysplastic syndromes'''
|-
|style="background-color:#fee0d2"|[[Chronic myeloid leukemia | Chronic myeloid leukemia (CML)]]
|style="background-color:#fee0d2"|[[Chronic myelomonocytic leukemia | Chronic myelomonocytic leukemia (CMML)]]
|style="background-color:#fee0d2"|[[Essential thrombocythemia | Essential thrombocythemia (ET)]]
|style="background-color:#fee0d2"|[[Hypereosinophilic syndrome| Hypereosinophilic syndrome (HES)]]
|-
|style="background-color:#fee0d2"|[[Myelodysplastic syndrome|Myelodysplastic syndrome (MDS)]]
|style="background-color:#fee0d2"|[[Myelofibrosis | Primary & secondary myelofibrosis (PMF/SMF)]]
|style="background-color:#fee0d2"|[[Myeloproliferative neoplasm, accelerated phase|Myeloproliferative neoplasm, accelerated phase (MPN-AP)]] <span style="color: red"><small>New</small></span>
|style="background-color:#fee0d2"|[[Polycythemia vera | Polycythemia vera (PV)]]
|-
|style="background-color:#fee0d2"|[[Systemic mastocytosis]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Aggressive lymphomas'''
|-
|style="background-color:#fee0d2"|[[Burkitt lymphoma|Burkitt lymphoma (BL) or Burkitt-like lymphoma]]
|style="background-color:#fee0d2"|[[Classical Hodgkin lymphoma|Classical Hodgkin lymphoma (cHL)]]
|style="background-color:#fee0d2"|[[CNS lymphoma]]
|style="background-color:#fee0d2"|[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]]
|-
|style="background-color:#fee0d2"|[[Diffuse large B-cell lymphoma, gastric|Gastric DLBCL]] <span style="color: red"><small>New</small></span>
|style="background-color:#fee0d2"|[[High-grade B-cell lymphoma|High-grade B-cell lymphoma (HGBL)]]
|style="background-color:#fee0d2"|[[HIV-associated lymphoma]]
|style="background-color:#fee0d2"|[[Mantle cell lymphoma|Mantle cell lymphoma (MCL)]]
|-
|style="background-color:#fee0d2"|[[Mediastinal gray-zone lymphoma|Mediastinal gray-zone lymphoma (MGZL)]]
|style="background-color:#fee0d2"|[[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBL)]]
|style="background-color:#fee0d2"|[[Transformed lymphoma|Transformed lymphoma (TL)]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Indolent lymphomas'''
|-
|style="background-color:#fee0d2"|[[Chronic lymphocytic leukemia| Chronic lymphocytic leukemia (CLL/SLL)]]
|style="background-color:#fee0d2"|[[Follicular lymphoma|Follicular lymphoma (FL)]]
|style="background-color:#fee0d2"|[[Hairy cell leukemia|Hairy cell leukemia (HCL)]]
|style="background-color:#fee0d2"|[[Hodgkin lymphoma, nodular lymphocyte-predominant|Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)]]
|-
|style="background-color:#fee0d2"|[[Indolent lymphoma|Indolent lymphoma (iNHL)]]
|style="background-color:#fee0d2"|[[B-cell lymphoma of mucosa-associated lymphoid tissue|MALT lymphoma]]
|style="background-color:#fee0d2"|[[Marginal zone lymphoma|Marginal zone lymphoma (MZL)]]
|style="background-color:#fee0d2"|[[Waldenström macroglobulinemia|Waldenström macroglobulinemia (WM/LPL)]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Plasma cell dyscrasias'''
|-
|style="background-color:#fee0d2"|[[Light-chain (AL) amyloidosis]]
|style="background-color:#fee0d2"|[[Multiple myeloma|Multiple myeloma (main page)]]
|style="background-color:#fee0d2"|[[Multiple_myeloma,_induction|MM,]] induction
|style="background-color:#fee0d2"|[[Multiple_myeloma,_consolidation_and_maintenance|MM, consolidation &]] maintenance
|-
|style="background-color:#fee0d2"|[[Multiple_myeloma,_relapsed-refractory|MM, relapsed/refractory]]
|style="background-color:#fee0d2"|[[Plasma cell leukemia|Plasma cell leukemia (PCL)]]
|style="background-color:#fee0d2"|[[POEMS syndrome]]
|style="background-color:#fee0d2"|[[Smoldering multiple myeloma|Smoldering multiple myeloma (SMM)]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''T-cell and NK-cell neoplasms'''
|-
|style="background-color:#fee0d2"|[[Adult T-cell leukemia-lymphoma|Adult T-cell leukemia-lymphoma (ATLL)]]
|style="background-color:#fee0d2"|[[Anaplastic large cell lymphoma|Anaplastic large cell lymphoma (ALCL)]]
|style="background-color:#fee0d2"|[[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]]
|style="background-color:#fee0d2"|[[Extranodal NK- and T-cell lymphoma, nasal type|Extranodal NK- and T-cell lymphoma, nasal type (ENKTCL-NT]]
|-
|style="background-color:#fee0d2"|[[Large granular lymphocytic leukemia|Large granular lymphocytic (LGL) leukemia]]
|style="background-color:#fee0d2"|[[NK- and T-cell lymphoma|NK- and T-cell lymphoma (NKTCL)]]
|style="background-color:#fee0d2"|[[Peripheral T-cell lymphoma|Peripheral T-cell Lymphoma (PTCL)]]
|style="background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic lymphoma (T-LBL)]]
|-
|style="background-color:#fee0d2"|[[T-cell prolymphocytic leukemia | T-cell prolymphocytic lymphoma (T-PLL)]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Lymphoproliferative disorders'''
|-
|colspan="2" style="background-color:#fee0d2"|[[Castleman disease]]
|colspan="2" style="background-color:#fee0d2"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Histiocytic disorders'''
|-
|style="background-color:#fee0d2"|[[Erdheim-Chester disease|Erdheim-Chester disease (ECD)]]
|style="background-color:#fee0d2"|[[Hemophagocytic lymphohistiocytosis|Hemophagocytic lymphohistiocytosis (HLH)]]
|style="background-color:#fee0d2"|[[Langerhans cell histiocytosis|Langerhans cell histiocytosis (LCH)]]
|style="background-color:#fee0d2"|[[Rosai-Dorfman-Destombes disease]]
|-
|}
<span id="peds"></span>
 
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#ba871a"|'''Pediatric Neoplasms'''
|-
|colspan="4" style="font-size:125%; background-color:#d1af67"|'''Pediatric CNS malignancies'''
|-
|style="width: 25%; background-color:#e8d7b3"|[[Low-grade glioma, pediatric|Low-grade glioma]]
|style="width: 25%; background-color:#e8d7b3"|[[High-grade glioma, pediatric|High-grade glioma]]
|style="width: 25%; background-color:#e8d7b3"|[[Medulloblastoma]]
|style="width: 25%; background-color:#e8d7b3"|
|-
|colspan="4" style="font-size:125%; background-color:#d1af67"|'''Pediatric hematologic neoplasms'''
|-
|style="background-color:#e8d7b3"|[[B-cell acute lymphoblastic leukemia, pediatric | B-cell acute lymphoblastic leukemia (B-ALL)]]
|style="background-color:#e8d7b3"|[[B-cell acute lymphoblastic leukemia, pediatric, Ph-positive | B-ALL, Ph+]]
|style="background-color:#e8d7b3"|[[T-cell acute lymphoblastic leukemia, pediatric | T-cell acute lymphoblastic leukemia (T-ALL)]]
|style="background-color:#e8d7b3"|[[Acute myeloid leukemia, pediatric | Acute myeloid leukemia (AML)]]
|-
|style="background-color:#e8d7b3"|[[Anaplastic large cell lymphoma, pediatric | Anaplastic large cell lymphoma (ALCL)]]
|style="background-color:#e8d7b3"|[[Chronic myeloid leukemia, pediatric | Chronic myeloid leukemia (CML)]]
|style="background-color:#e8d7b3"|[[Juvenile myelomonocytic leukemia | Juvenile myelomonocytic leukemia (JMML)]]
|-
|style="background-color:#e8d7b3"|[[Classical Hodgkin lymphoma, pediatric |Classical Hodgkin lymphoma (cHL)]]
|style="background-color:#e8d7b3"|[[Non-Hodgkin lymphoma, pediatric | Non-Hodgkin lymphoma (NHL)]]
|-
|colspan="4" style="font-size:125%; background-color:#d1af67"|'''Pediatric solid tumors'''
|-
|style="background-color:#e8d7b3"|[[Epithelioid sarcoma]]
|style="background-color:#e8d7b3"|[[Ewing sarcoma, pediatric|Ewing sarcoma]]
|style="background-color:#e8d7b3"|[[Hepatoblastoma]]
|style="background-color:#e8d7b3"|[[Neuroblastoma]]
|-
|style="background-color:#e8d7b3"|[[Osteosarcoma, pediatric|Osteosarcoma]]
|style="background-color:#e8d7b3"|[[Retinoblastoma]]
|style="background-color:#e8d7b3"|[[Rhabdomyosarcoma, pediatric|Rhabdomyosarcoma]]
|style="background-color:#e8d7b3"|[[Wilms tumor]]
|-
|}
<span id="transplant"></span>
 
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#4a1486"|'''Transplant and Immune Effector Cells (IECs)'''
|-
|style="width: 25%; background-color:#efedf5"|[[Stem cell mobilization]]
|style="width: 25%; background-color:#efedf5"|[[Allogeneic HSCT]]
|style="width: 25%; background-color:#efedf5"|[[Autologous HSCT]]
|style="width: 25%; background-color:#efedf5"|[[Chimeric antigen receptor T cells (CAR-T)]]
|-
|style="background-color:#efedf5"|[[Graft versus host disease|Graft versus host disease (GVHD)]]
|style="background-color:#efedf5"|[[Hepatic veno-occlusive disease|Hepatic veno-occlusive disease (VOD/SOS)]]
|-
|}
<span id="classicalheme"></span>
 
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
|colspan="4" align="center" style="color:white; font-size:150%; background-color:#31a354"|'''Classical Hematology'''
|-
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Hemostasis and thrombosis'''
|-
|style="width: 25%; background-color:#e5f5e0"|[[Acquired coagulopathy]]
|style="width: 25%; background-color:#e5f5e0"|[[Acquired thrombotic thrombocytopenic purpura|Acquired thrombotic thrombocytopenic purpura (aTTP)]]
|style="width: 25%; background-color:#e5f5e0"|[[Antiphospholipid antibody syndrome|Antiphospholipid antibody syndrome (APLAS)]]
|style="width: 25%; background-color:#e5f5e0"|[[Congenital thrombotic thrombocytopenic purpura|Congenital thrombotic thrombocytopenic purpura (cTTP)]]
|-
|style="width: 25%; background-color:#e5f5e0"|[[Hemophilia A]]
|style="width: 25%; background-color:#e5f5e0"|[[Hemophilia B]]
|style="width: 25%; background-color:#e5f5e0"|[[Heparin-induced thrombocytopenia|Heparin-induced thrombocytopenia (HIT)]]
|style="width: 25%; background-color:#e5f5e0"|[[Hereditary hemorrhagic telangiectasia|Hereditary hemorrhagic telangiectasia (HHT)]]
|-
|style="background-color:#e5f5e0"|[[Inherited thrombophilia]]
|style="background-color:#e5f5e0"|[[Thrombotic microangiopathy|Thrombotic microangiopathy (TMA)]]
|style="background-color:#e5f5e0"|[[Venous thromboembolism|Venous thromboembolism (VTE)]]
|style="background-color:#e5f5e0"|[[Von Willebrand disease|von Willebrand disease (vWD)]]
|-
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Cytopenias'''
|-
|style="background-color:#e5f5e0"|[[Aplastic anemia]]
|style="background-color:#e5f5e0"|[[Autoimmune cytopenia]]
|style="background-color:#e5f5e0"|[[Immune thrombocytopenia|Immune thrombocytopenia (ITP)]]
|style="background-color:#e5f5e0"|[[Thrombocytopenia in liver disease]]
|-
|style="background-color:#e5f5e0"|[[WHIM syndrome]]
|-
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Hemolytic disorders and Hemoglobinopathies'''
|-
|style="background-color:#e5f5e0"|[[Atypical hemolytic uremic syndrome|Atypical hemolytic uremic syndrome (aHUS)]]
|style="background-color:#e5f5e0"|[[Warm autoimmune hemolytic anemia|Warm autoimmune hemolytic anemia (WAIHA)]]
|style="background-color:#e5f5e0"|[[Cold agglutinin disease|Cold agglutinin disease (CAD)]]
|style="background-color:#e5f5e0"|[[Paroxysmal nocturnal hemoglobinuria|Paroxysmal nocturnal hemoglobinuria (PNH)]]
|-
|style="background-color:#e5f5e0"|[[Pyruvate kinase deficiency|Pyruvate kinase deficiency (PKD)]]
|style="background-color:#e5f5e0"|[[Beta thalassemia]]
|style="background-color:#e5f5e0"|[[Sickle cell disease|Sickle cell disease (SCD)]]
|-
|}
 
<div style="text-align:center"><big>'''[[Special:AllPages|Browse our complete index of pages]]'''</big></div>
 
==Additional Information==
Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about hundreds of hematology/oncology drugs, and thousands of treatment regimens. Content is added by hematology & oncology professionals, and undergoes [[how to contribute|continuous peer review]].
 
Any information that one feels would be helpful to other oncology providers is welcome. Visit [[how to contribute]] for more details.
 
Priorities of this project include:
<section begin=goals />
*'''Creating a database of all [[Drug index | approved systemic anticancer therapy agents and supportive medications used in the field of hematology/oncology]].
*'''Creating a database of all standard-of-care systemic anticancer therapy regimens and references to primary literature.
*'''[[:Category:Example chemotherapy order sets|Sample order sets]] and examples of supportive medications used with treatment regimens
*'''Aggregating [[External links|useful links]] to existing resources by disease, such as guidelines, information about prognosis, clinical calculators, staging, and patient resources.
*'''Creating, maintaining, and disseminating a [[Ontology|formalized ontology]] of anticancer drugs and regimens.
<section end=goals />
 
Additional possibilities for this project may include:
*Creating synopses of pivotal clinical trials and regimens
*Prioritizing regimens by their efficacy and/or toxicity
*Capturing historical regimens that were standard-of-care prior to 2005
*Checklists for common clinical scenarios/diseases
*Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects
 
The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as [https://en.wikipedia.org/wiki/Main_Page Wikipedia], will significantly help ease-of-use and navigation.
 
<br><inputbox>
type=create
width=70
placeholder=Type the name of the page you want to create
break=no
</inputbox>

Latest revision as of 06:20, 16 October 2026

%About_Yourself%

Retrieved from "https://neoplasm.org/index.php?title=Main_Page&oldid=592009"